Skip to content

Sleep Subtypes in Adolescent Depression

Sleep Subtypes in Adolescent Depression: Sleep Physiology and Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03742960
Enrollment
71
Registered
2018-11-15
Start date
2019-04-24
Completion date
2023-07-01
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

The purpose of this study is to compare sleep neurophysiology and behavior in adolescents with MDD with hypersomnia (MDD-HYP) and insomnia (MDD-INS) with healthy controls (HC). In addition, the investigators will test the efficacy of a simple behavioral sleep restriction on mood and sleep in their sample.

Detailed description

The World Health Organization has identified depression as the leading cause of burden of disease amongst young people. Subjective sleep complaints are often a core symptom of depression and highly prevalent with 60-90% of depressed adolescents suffering from disrupted sleep. This sleep disruption often takes the form of insomnia (e.g., difficulty falling or staying asleep, or waking too early) or hypersomnia (prolonged sleep episodes or excessive daytime sleepiness). The aim of the trial is to examine the efficacy of a simple behavioral sleep restriction two weeks in duration on mood and sleep in adolescents ages 14 to 17 years with and without major depressive disorder. During this period sleep is objectively measured using actigraphy and monitor mood using self-report. The results of the study will inform whether a simple behavioral sleep restriction beneficially impacts mood and sleep.

Interventions

BEHAVIORALBehavioral Sleep Restriction

Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.

Sponsors

University Hospital for Child and Adolescent Psychiatry and Psychotherapy Bern
CollaboratorUNKNOWN
University of Bern
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to 17 Years
Healthy volunteers
Yes

Inclusion criteria

\- This study will recruit adolescents (ages 14 to 17 years) with major depressive disorder (MDD) with insomnia (MDD-INS) and with hypersomnia (MDD-HYP) and age and gender matched controls (HC). Inclusion Criteria: Key inclusion criteria for MDD Hypersomnia Group: * MDD as determined through the MINI-KID * Determination of hypersomnia as defined by excessive daytime sleepiness, or long sleep duration. * Written informed consent Key inclusion criteria for MDD Insomnia Group: * MDD as determined through the MINI-KID * Determination of insomnia as defined by the insomnia severity index * Written informed consent

Exclusion criteria

* Key

Design outcomes

Primary

MeasureTime frameDescription
Change in self-reported sleep efficiency (defined as total sleep time divided by time in bed and thus expressed as a percentage) as assessed via sleep diaryTwo weeksChanges in self-reported sleep efficiency will be measured via sleep diary. The data will be collected by ecological momentary assessment (EMA). Time in bed (TIB) is defined as the time between participants reporting going to bed and waking up. Total sleep time (TST) is defined as TIB minus the amount of time participants report taking to fall asleep (sleep onset latency; SOL) and the duration of waking after sleep onset (WASO).
Change in self-reported mood assessed via the Multidimensional Mood QuestionnaireTwo weeksChanges in self-reported mood will be measured via ecological momentary assessment. Participants will fill out the Multidimensional Mood Questionnaire four times a day (morning, after school, at dusk and 30 minutes before bedtime). The Multidimensional Mood Questionnaire assesses the state happy/sad on a visual analog scale from 0 to 100. The mean across the day will be calculated.

Secondary

MeasureTime frameDescription
Change in Repetitive Negative Thinking (focus on problems) assessed by one question from the Response Style QuestionnaireTwo weeksChange in repetitive negative thinking will be measured via ecological momentary assessment. Participants will answer the question about focus on problems on a scale from 0 \[not at all\] to 100 \[very much\]) once a day (evening).
Change in Repetitive Negative Thinking (focus on feelings) assessed by one question from the Response Style QuestionnaireTwo weeksParticipants will answer the question about focus on feelings on a scale from 0 \[not at all\] to 100 \[very much\]) once a day (evening).
Change in depressive symptoms from 1 to 3 days prior to the sleep manipulation and the end of the manipulation (second to last or last day of sleep manipulation)Two weeksThe change in depressive symptoms from 1 to 3 days prior to the sleep manipulation and the end of the manipulation (second to last or last day of sleep manipulation) will be measured via Center for Epidemiological Studies-Depression (CES-D; measures symptoms associated with depression), Strengths & Difficulties Questionnaires (SDQ; measures strengths and difficulties in general) and the Assessment of Snaith-Hamilton Pleasure Scale (SHAPS; assesses the presence of anhedonia \[the inability to experience pleasure\].
Change in anxiety symptoms from 1 to 3 days prior to the sleep manipulation and the end of the manipulation (second to last or last day of sleep manipulation)Two weeksThe change in depressive symptoms from 1 to 3 days prior to the sleep manipulation and the end of the manipulation (second to last or last day of sleep manipulation) will be measured via Screen for Child Anxiety-Related Emotional Disorders (SCARED; screens anxiety disorder categories).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026